Shots:

• The FDA has approved the Oncomine Dx target test as a CDx to identify patients with IDH1 mutated CCA who may be candidates for Servier’s Tibsovo
• Oncomine Dx Target Test is NGS based CDx test that provides robust results in the IDH1 gene clinically associated with CCA & is currently approved in 15+ countries- including the US- EU- Japan- South Korea & Middle East. The test had received the 1st FDA's approval in 2017 & is now approved for 4 targeted therapies for NSCLC & 1 for CCA in the US
• Thermo Fisher & Servier collaborated to develop & commercialize a CDx supporting Oncomine precision assay to identify LGG patients with IDH1 & 2 mutations who may be eligible for vorasidenib

| Ref: PR Newswire | Image: CPhl Online